Roquefort Therapeutics CEO discusses MK cell therapy patent and other milestones

Roquefort Therapeutics PLC chief executive Ajan Reginald takes Proactive Stephen Gunnion through the significant progress the company has made over the summer, including advancing key programs and securing a European patent for its MK cell therapy. Reginald highlighted the MK cell's unique ability to activate the body's natural killer cells, offering promising applications in both oncology and immunology. This patent covers 39 countries, protecting both the composition of the MK cells and their use in conjunction with natural killer cells. Discussing the company’s next steps, Reginald pointed to the potential transformational impact of ongoing deals and the expansion of Roquefort’s immunology and oncology franchises. "As mentioned in the RNS, it should be a transformational quarter for us," Reginald stated, reflecting the company’s strategic focus on developing and commercializing these cutting-edge therapies. Stay tuned for more updates on Roquefort Therapeutics’ progress. Don’t forget to like the video, subscribe to our channel, and enable notifications for future content. #RoquefortTherapeutics #Immunology #Oncology #MKCellTherapy #BiotechNews #CellTherapy #Pharmaceuticals #CancerResearch #PatentAward #InvestingInBiotech#proactiveinvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews